Loading
A phase 3 trial of Azacitidine and Decitabine in myelodysplastic syndromes / neoplasms, run by Otsuka Australia Pharmaceutical Pty Ltd, active and no longer recruiting.
A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia is a phase 3 interventional study registered as NCT05883956 by Otsuka Australia Pharmaceutical Pty Ltd, with 13 participants enrolled, started 2023-12-20 and due to reach its primary completion in 2024-12-06. Interventions recorded: Subcutaneous azacitidine and Oral decitabine/cedazuridine.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Myelodysplastic syndromes / neoplasms (MDS), Cytotoxic chemotherapy and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Azacitidine, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Decitabine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Myelodysplastic syndromes / neoplasms (MDS), Cytotoxic chemotherapy and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.